JPRN-jRCT1061200062招募中2 期
The efficacy and safety of pembrolizumab plus axitinib combination thrapy for unresectable or metastatic non-clear cell renal carcinoma. - pembrolizumab plus axitinib trial
Takehiro Iawata0 个研究点目标入组 7 人开始时间: 2021年3月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients of unresectable or metastatic non-clear cell renal carcinoma without history of drug treatment.
排除标准
- •Karnofsky performance-status<70
- •Patients with autoimmune disease.
- •Patients with ischemic heart disease or New York Heart Association class 3 or 4 heart failure within the past year.
- •Patients receiving dialysis treatment.
- •Patients with a history of hypersensitivity for pembrolizumab or axitinib.
- •Pregnant patients.
- •Patients with liver dysfunction for Child- Pugh score B or C.
研究者
相似试验
已完成
不适用
Safety and efficacy of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status: a pilot study.non-small cell lung cancerJPRN-UMIN000029601Hiroshima University Hospital30
已完成
不适用
Safety and efficacy of pembrolizumab as first-line treatment in elderly patients with non-small cell lung cancer: a pilot study.on-small cell lung cancerJPRN-UMIN000029602Department of Respiratory Internal medicine, Hiroshima Univestity Hospital35
进行中（未招募）
2 期
A phase 2 study of pembrolizumab in combination with olaparib in patients with cervical cancer previously treated with platinum-based chemotherapyrecurrent or metastatic cervical cancercervical cancer ,Pembrolizumab,OlaparibJPRN-jRCT2031210096Hasegawa Kosei28
招募中
2 期
Clinical trial of combined therapy with pembrolizumab and lenvatinib for patients with classic Kaposi sarcoma treated with at least one previous line of chemioterapy.2024-512834-14-00Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico25
进行中（未招募）
1 期
Pembrolizumab With or Without Maintenance MK-2870 in Metastatic Squamous NSCLCParticipants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)MedDRA version: 24.0Level: LLTClassification code: 10085300Term: Squamous non-small cell lung cancer Class: 100000004848CTIS2023-510128-66-00Merck Sharp & Dohme LLC800